Addex H1 FY26 net loss widens 4.29% to CHF 3.46 million; operating loss narrows 15.98% to CHF 1.13 million

• Addex Therapeutics posted a H1 net loss of CHF 3.46 million, widening 4.28% from a year earlier; EPS held at CHF 0.03.
• Operating loss narrowed 15.98% to CHF 1.13 million, while R&D costs fell 81.07% to CHF 74,000.
• Cash and equivalents slid 66.67% to CHF 767,000 at June 30.
• Subsequent to quarter-end, gross proceeds totaled CHF 2.3 million from 52,970,533 shares sold at an average CHF 0.043.
• Management cited advancing its in-house GABAB cough program and regaining GABAB PAM rights from Indivior; Neurosterix’s NTX-253 Phase 1 readout targeted for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Addex Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280100PRIMZONEFULLFEED1001274819) on September 28, 2026, and is solely responsible for the information contained therein.